chr2-188999357-G-T
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM2PP2PP3_StrongPP5
The NM_000090.4(COL3A1):c.2095G>T(p.Gly699Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (no stars).
Frequency
Consequence
NM_000090.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL3A1 | ENST00000304636.9 | c.2095G>T | p.Gly699Cys | missense_variant | Exon 30 of 51 | 1 | NM_000090.4 | ENSP00000304408.4 | ||
COL3A1 | ENST00000450867.2 | c.1996G>T | p.Gly666Cys | missense_variant | Exon 29 of 50 | 1 | ENSP00000415346.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Ehlers-Danlos syndrome, type 4 Pathogenic:1
The vascular Ehlers-Danlos syndrome (EDS), also known as type IV EDS, is associated with arterial, digestive, and uterine complications, including intestinal perforation, rarely manifest in other types of EDS. The variants of the COL3A1 gene have been reported including c.2095G>C, p.Gly699Arg and c.2095G>A, p.Gly699Asp (Pepin 2014). Herein we describe a novel likely pathogenic variant, a missense mutation in the COL3A1gene (c.2095G>T, p.Gly699Cys) detected in the Japanese family with typical symptoms of type IV EDS including multiple intestinal perforations or aortic rupture. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.